c-KIT positive Gastrointestinal Stromal Tumor presenting with acute bleeding in a patient with neurofibromatosis type 1: a case report
© Aboutaleb et al; licensee BioMed Central Ltd. 2009
Received: 25 June 2009
Accepted: 23 October 2009
Published: 23 October 2009
Gastrointestinal stromal tumours are rare (GIST). However, the incidence of GIST among neurofibromatosis type 1 (NF-1) patients is approximately 3.9-25%. GIST can present clinically in different ways such as abdominal pain, gastrointestinal bleeding and obstruction.
We present 51 year female patient admitted with Background of neurofibromatosis type 1 admitted with melena. OGD has been done and showed duodenitis with large volume fresh blood in distal duodenum but no obvious bleeding point. Exploratory laparotomy revealed smooth nodular masses on the serosal surface of jejunum. Small bowel resection and side-to-side anastomosis were performed. Histopathoogical examination revealed small bowel gasrointestinal stromal tumour with low risk malignant potential.
The incidence of GIST among neurofibromatosis type 1 (NF-1) patients is not uncommon and we should pay attention to gastrointestinal manifestation in such patients.
Neurofibromatosis is an autosomal dominant disorder that affects all 3 germinal layers; thereby affecting any organ system. The National Institutes of Health (NIH) Consensus Development Conference has defined 2 distinct types: the commoner of the two, neurofibromatosis type 1 (NF1) affecting 85% of patients; and neurofibromatosis type 2 (NF2) . NF1diagognsis made if 2 or more of following criteria found: Six or more café au lait macules larger than 5 mm, two or more neurofibromas, multiple freckles, A distinctive osseous lesion, optic glioma, two or more iris hamartomas, a first-degree relative with NF1. Rarely, the neurofibromatosis may become cancerous (3-5%). Gastrointestinal stromal tumours (GIST) are generally rare however; the incidence of GIST among NF-1 patients is approximately 5-25% . GISTs are usually located in the stomach and small intestine and can present in a variety of different ways ranging from vague symptoms to major G.I. bleeding. The first line treatment is surgical resection for operable GIST and 5-year survival ranges from 21% to 88% depending on risk grading and completeness of surgical resection [3, 4]. The second line of treatment is Imatinib mesylate, a tyrosine kinase inhibitor, which provides an option for treating high risk GISTs.
We report the case of a 51 year female patient with NF-1 who presented with lower GI bleeding caused by a jejunal GIST.
A 51 year old lady with NF-1 as she has multiple neurofibromas and seven café au lait macules larger than 5 mm. Presented to A&E with a 24 hour history of malena. She was on warfarin for aortic root and valve replacement surgery she had in the previous year. Although she remained haemodynamically stable, her haemoglobin levels gradually dropped 4 units over the next 36 hours. Along with correction of her clotting function, investigations were initiated that included an upper GI endoscopy which revealed blood in the second part of duodenum. Due to a rapid deterioration in her haemodynamic status colonoscopy was cancelled and a mesenteric angiogram was done that suggested bleeding from the region between the 4th part of duodenum and upper jejunum from intestinal mass. She was subjected to emergency laparotomy. At surgery, smooth nodular masses were found on the serosal surface of the first 50 cm of jejunum; these were 3-4 cm and projected into the lumen having eroded the mucosal surface. Resection of the affected segment and end to end anastomosis was performed. The rest of the bowel appeared free of any masses and after concluding surgery the patient was transferred to ITU postoperatively. She made an uncomplicated recovery and was discharged 7 days after operation. A subsequent CT scan did not reveal any other masses.
Abdominal involvement in NF-1 has been described before. This includes GISTs , pheochromocytomas  and ampullary tumours . 78% of sporadic GISTs show c-KIT mutations . However, this typical mutation is rarely seen in NF-1 associated GISTs [5, 9] leading to authors proposing an alternative pathogenesis of GISTs in NF-1 patients . This has potential implications for Imatinib therapy when required as this is likely to be ineffective in c-KIT negative ones as in NF-1 .
Figure 1- Gastro-intestinal stromal tumour (GIST) in small bowel, arising from the submucosa (haematoxylin and eosin; original magnification × 40)
Our patient possessed the known c-KIT mutation that does not appear typical of NF-1 associated GISTs from review of literature. It may be that our patient developed a GIST by co-incidence rather than as an association with NF-1. However the finding of a low malignant potential GIST in our patient based on mitotic count is consistent with other NF-1 associated GISTs reported, along with other features like young age and female preponderance .
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
To R Ahmed who provides us with histopathology slides
- NIH: Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988, 45 (5): 575-8.View ArticleGoogle Scholar
- Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR: Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol. 2005, 18 (4): 475-84. 10.1038/modpathol.3800334.View ArticlePubMedGoogle Scholar
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodriff JM, Brennan MF: Two hundred gastro-intestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-8. 10.1097/00000658-200001000-00008.PubMed CentralView ArticlePubMedGoogle Scholar
- Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R: Outcome and long-term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg. 2003, 92: 195-199.PubMedGoogle Scholar
- Miettinen M, Fetsch JF, Sobin LH, Lasota J: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006, 30 (1): 90-6. 10.1097/01.pas.0000176433.81079.bd.View ArticlePubMedGoogle Scholar
- Teramoto S, Ota T, Maniwa A, Matsui T, Itaya N, Aoyagi K, Kusanagi H, Narita M: Two von Recklinghausen's disease cases with pheochromocytomas and gastrointestinal stromal tumors (GIST) in combination. Int J Urol. 2007, 14 (1): 73-4. 10.1111/j.1442-2042.2006.01601.x.View ArticlePubMedGoogle Scholar
- Behranwala KA, Spalding D, Wotherspoon A, Fisher C, Thompson JN: Small bowel gastrointestinal stromal tumours and ampullary cancer in Type 1 neurofibromatosis. World J Surg Oncol. 2004, 2: 1-10.1186/1477-7819-2-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004, 22 (18): 3813-25. 10.1200/JCO.2004.05.140.View ArticlePubMedGoogle Scholar
- Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, Yokoyama S, Motegi A, Fukayama M: Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol. 2005, 29 (6): 755-63. 10.1097/01.pas.0000163359.32734.f9.View ArticlePubMedGoogle Scholar
- Stewart DR, Corless CL, Rubin BP, Heinrich MC, Messiaen LM, Kessler LJ, Zhang PJ, Brooks DG: Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. J Med Genet. 2007, 44 (1): e61-10.1136/jmg.2006.043075.PubMed CentralView ArticlePubMedGoogle Scholar
- Frost MJ, Ferrao PT, Hughes TP, Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c- kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002, 1 (12): 1115-24.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.